(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 January 2023 (26.01.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/004075 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/506* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2022/037928

(22) International Filing Date:
21 July 2022 (21.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/224,208 21 July 2021 (21.07.2021) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **WU, Tian**; C/O AMGEN INC., ONE AMGEN CENTER DRIVE, M/S 28-5-A, LAW-PATENT OPERATIONS, THOUSAND OAKS, California 91320-1799 (US). **AGARWAL, Prashant**; C/O AMGEN INC., ONE AMGEN CENTER DRIVE, M/S 28-5-A, LAW-PATENT OPERATIONS, Thousand Oaks, California 91320-1799 (US). **ROTHELI, Andreas R.**; C/O AMGEN INC., ONE AMGEN CENTER DRIVE, M/S 28-5-A, LAW-PATENT OPERATIONS, Thousand Oaks, California 91320-1799 (US). **PARK, Hyunsoo**; c/o AMGEN INC., ONE AMGEN CENTER DRIVE, M/S 28-5-A, LAW-PATENT OPERATIONS, THOUSAND OAKS, California 91320-1799 (US). **FROHN, Michael J.**; c/o AMGEN INC., ONE AMGEN CENTER DRIVE, M/S 28-5-A, LAW-PATENT OPERATIONS, THOUSAND OAKS, California 91320-1799 (US).

(74) Agent: **LEMOINE, Elsa D.**; AMGEN INC., ONE AMGEN CENTER DRIVE, M/S 28-5-A, LAW-PATENT OPERATIONS, THOUSAND OAKS, California 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

(54) Title: SALTS AND SOLID STATE FORMS OF A KIF18A INHIBITOR COMPOUND

FIG. 1



(57) **Abstract:** Disclosed herein is a salt, a crystalline anhydrous form, a hydrate, a solvate, or a co-crystal of a free base compound 2-(6-azaspiro[2.5]octan-6-yl)-*N*-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-[(2-hydroxyethanesulfonyl)amino]benzamide (Compound A); method of preparation, pharmaceutical compositions, and method of treating a disease mediated by a motor protein kinesin family member 18A (KIF18A) inhibition, wherein said disease is a neoplastic disease, including a cancer or a tumor.

WO 2023/004075 A1

[Continued on next page]

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*